GT Biopharma, Inc. Segments Disclosure
Note 9 – Segment Information
The Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The measure of segment assets is reported on the balance sheet as total assets.
The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.
Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:
| Year Ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Research and development | $ | 5,798,000 | $ | 6,466,000 | ||||
| Salaries | 1,095,000 | 1,153,000 | ||||||
| Insurance | 271,000 | 353,000 | ||||||
| Stock-based compensation | 230,000 | 2,200,000 | ||||||
| Operating expenses | 4,566,000 | 3,386,000 | ||||||
| Other (income) expense | 1,202,000 | (5,979,000 | ) | |||||
| Net loss | $ | 13,162,000 | $ | 7,579,000 | ||||
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.